ChemoMetec growth outlook raised on instrument sales
ChemoMetec reported revenue rising 3% to DKK 511 million, EBITDA margin at 55%, with life science making up 95% of revenue and next-year revenue growth guidance of 7–13%.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.